Performance of plasma p-tau217 in distinguishing amyloid and tau pathology differs by cognitive impairment status

Key Points

• Plasma p-tau217 effectively distinguishes between amyloid and tau pathology in patients with cognitive impairment.
• A significant accuracy rate of 85% was observed, supporting its utility as a biomarker.
• Assessment involved a comprehensive analysis of cognitive impairment status across various participants.
• Further validation is needed to establish p-tau217's role in routine clinical practice for diagnosing Alzheimer's disease.